Section I. Cholinergic drugs for Alzheimer's Disease: Mechanisms, emerging and future evolution 1. Introduction 2. Current hypothesis for Alzheimer's Disease progression 3. Neurotransmitter (NT) systems and peripheral nerve system (PNS) 4. ACh receptors in Ach transmission 5. Choline esterase 6. Cholinergic ACh, AChE, and its inhibitors 7.
Classification of ChE inhibitors by binding mode 8. Classification of ChE inhibitors by activation mechanism 9. Clinical status of ChE inhibitors 10. ChE inhibitors 11. Forthcoming generation of AChE inhibitors 12. Hybrid inhibitors 13. AChE-targeted drugs for Alzheimer's Disease treatment 14. Cholinergic neuromuscular junction and its blocking agents (blockers) 15.
Non-adrenergic and non-cholinergic (NANC) neurotransmitters 16. Protein kinase inhibitors for treatment of Alzheimer's Disease 17. Inhibition of cholinergic inflammation via AChE inhibitor interaction with α4β2 nAChE and α7nAChR, not AChE enzyme inhibition 18. NMDA and non-NMDA receptor antagonism for Alzheimer's Disease treatment 19. Challenges in recent Alzheimer's Disease therapeutic approaches 20. Identification and application of biomarkers for Alzheimer's Disease 21. Artificial Intelligence (AI)-assisted Alzheimer's Disease target and drug discovery 22. Conclusion and perspectives Section II.
Natural alkaloidal and non-alkaloidal anti-AChE and anti-Alzheimer's Disease compounds in the symptomatic intimation of Alzheimer's Disease 23. Introduction 24. Current bioactive molecules in Alzheimer's Disease therapy 25. Emerging lead compounds from natural bioactive molecules for Alzheimer's Disease therapy 26. Natural anti-AChE compounds for Alzheimer's Disease therapy 27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities 28. Conceptual search for MTDs of natural plant compounds for multifactorial Alzheimer's Disease therapy 29. AChE inhibitors of daily-consumable cereals and food resources 30.
Conclusion and perspectives Section III. Marine AChE inhibitors for the symptomatic treatment of Alzheimer's Disease 31. Introduction 32. Localization, structure and cellular function of AChE 33. AChE inhibitors from marine resources 34. Non-ChE inhibitory anti-Alzheimer's Disease compounds 35. Emerging concept of dual-target drug (DTD) and multi-target drug (MTD) in Alzheimer's Disease pathology and promising Alzheimer's Disease drugs 36. Conclusion and perspectives.